Movatterモバイル変換

Desvenlafaksin

С Википедије, слободне енциклопедије

Desvenlafaksin
Klinički podaci


Prodajno ime	Pristiq, Zyven-OD
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	11,1 h
Izlučivanje	Renalno

Identifikatori
CAS broj	93413-62-8^Y
ATC kod	N06AX23 (WHO)
PubChem	CID125017
DrugBank	DB06700^Y
ChemSpider	111300^Y
ChEMBL	CHEMBL1118^Y
Hemijski podaci
Formula	C₁₆H₂₅NO₂
Molarna masa	263,375
SMILES CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
InChI InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3^Y Key:KYYIDSXMWOZKMP-UHFFFAOYSA-N^Y

Desvenlafaksin jeorgansko jedinjenje, koje sadrži 16atoma ugljenika i imamolekulsku masu od 263,375Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]^[14]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	2
Broj rotacionih veza	4
Particioni koeficijent^[15] (ALogP)	2,8
Rastvorljivost^[16] (logS, log(mol/L))	-3,2
Polarna površina^[17] (PSA,Å²)	43,7

Reference

[уреди |уреди извор]

^Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of Infant Dose Through Milk in a Lactating Woman Taking Amisulpride and Desvenlafaxine for Treatment-Resistant Depression. Ther Drug Monit. 5.Ilett, K. F.; Watt, F.; Hackett, L. P.; Kohan, R.; Teoh, S. (2010 Oct). „Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression”.Therapeutic Drug Monitoring.32 (6): 704—707.PMID 20926994.doi:10.1097/FTD.0b013e3181f88f70. Проверите вредност парамет(а)ра за датум:|date= (помоћ)
^Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother.Kamath, J.; Handratta, V. (децембар 2008). „Desvenlafaxine succinate for major depressive disorder: A critical review of the evidence”.Expert Review of Neurotherapeutics.8 (12): 1787—97.PMID 19086875.doi:10.1586/14737175.8.12.1787. CS1 одржавање: Формат датума (веза)
^Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry.Kornstein, S. G.; Jiang, Q.; Reddy, S.; Musgnung, J. J.; Guico-Pabia, C. J. (август 2010). „Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder”.The Journal of Clinical Psychiatry.71 (8): 1088—96.PMID 20797382.doi:10.4088/JCP.10m06018blu. CS1 одржавање: Формат датума (веза)
^Liebowitz MR, Tourian KA: Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder:A Systematic Review of Clinical Trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845.Liebowitz, M. R.; Tourian, K. A. (2010).„Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/D for the treatment of major depressive disorder:a systematic review of clinical trials”.Primary Care Companion to the Journal of Clinical Psychiatry.12 (3).PMC 2947544 .PMID 20944767.doi:10.4088/PCC.09r00845blu.
^Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther.Mason, J. N.; Deecher, D. C.; Richmond, R. L.; Stack, G.; Mahaney, P. E.; Trybulski, E.; Winneker, R. C.; Blakely, R. D. (новембар 2007). „Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter”.The Journal of Pharmacology and Experimental Therapeutics.323 (2): 720—9.PMID 17673606.doi:10.1124/jpet.107.125716. CS1 одржавање: Формат датума (веза). Epub 2007 Aug 2.
^Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA: Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol.Montgomery, S. A.; Fava, M.; Padmanabhan, S. K.; Guico-Pabia, C. J.; Tourian, K. A. (новембар 2009). „Discontinuation symptoms and taper/Poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder”.International Clinical Psychopharmacology.24 (6): 296—305.PMID 19779354.doi:10.1097/YIC.0b013e32832fbb5a. CS1 одржавање: Формат датума (веза)
^Oganesian A, Shilling AD, Young-Sciame R, Tran J, Watanyar A, Azam F, Kao J, Leung L: Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol Bull. 2009;Oganesian, A.; Shilling, A. D.; Young-Sciame, R.; Tran, J.; Watanyar, A.; Azam, F.; Kao, J.; Leung, L. (2009). „Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities”.Psychopharmacology Bulletin.42 (2): 47—63.PMID 19629022.
^Pae CU, Park MH, Marks DM, Han C, Patkar AA, Masand PS: Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. Curr Opin Investig Drugs.Pae, C. U.; Park, M. H.; Marks, D. M.; Han, C.; Patkar, A. A.; Masand, P. S. (јануар 2009). „Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause”.Current Opinion in Investigational Drugs (London, England : 2000).10 (1): 75—90.PMID 19127490. CS1 одржавање: Формат датума (веза)
^Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin.Reddy, S.; Kane, C.; Pitrosky, B.; Musgnung, J.; Ninan, P. T.; Guico-Pabia, C. J. (јануар 2010). „Clinical utility of desvenlafaxine 50 mg/D for treating MDD: A review of two randomized placebo-controlled trials for the practicing physician”.Current Medical Research and Opinion.26 (1): 139—50.PMID 19919295.doi:10.1185/03007990903408678. CS1 одржавање: Формат датума (веза)
^Wyeth Laboratories Inc. Pristiq (desvenlafaxine succinate) extended-release tablets prescribing information. Philadelphia, PA; 2010 Sept.
^Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother.Pae, Chi-Un (децембар 2011). „Desvenlafaxine in the treatment of major depressive disorder”.Expert Opinion on Pharmacotherapy.12 (18): 2923—8.PMID 22098230.doi:10.1517/14656566.2011.636033. CS1 одржавање: Формат датума (веза)..
^Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol.Preskorn, Sheldon; Patroneva, Albena; Silman, Heather; Jiang, Qin; Isler, Jennifer A.; Burczynski, Michael E.; Ahmed, Saeeduddin; Paul, Jeffrey; Nichols, Alice I. (фебруар 2009). „Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers”.Journal of Clinical Psychopharmacology.29 (1): 39—43.PMID 19142106.doi:10.1097/JCP.0b013e318192e4c1. CS1 одржавање: Формат датума (веза)..
^Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011).„DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”.Nucleic Acids Research.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008).„DrugBank: A knowledgebase for drugs, drug actions and drug targets”.Nucleic Acids Research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”.The Journal of Physical Chemistry A.102 (21): 3762—3772.Bibcode:1998JPCA..102.3762G.doi:10.1021/jp980230o.
^Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”.Journal of Chemical Information and Computer Sciences.41 (6): 1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”.Journal of Medicinal Chemistry.43 (20): 3714—3717.PMID 11020286.doi:10.1021/jm000942e.